Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Benzodiazepine receptor quantification in Huntington's disease with [I-123]iomazenil and SPECT
Autore:
Pinborg, LH; Videbaek, C; Hasselbalch, SG; Sorensen, SA; Wagner, A; Paulson, OB; Knudsen, GM;
Indirizzi:
Rigshosp, Neurobiol Res Unit 9201, DK-2100 Copenhagen, Denmark Rigshosp Copenhagen Denmark DK-2100 it 9201, DK-2100 Copenhagen, Denmark IMBG, Panum Inst, Inst Med Genet, DK-2200 Copenhagen, Denmark IMBG Copenhagen Denmark DK-2200 t Med Genet, DK-2200 Copenhagen, Denmark Rigshosp, Dept Radiol, DK-2100 Copenhagen, Denmark Rigshosp Copenhagen Denmark DK-2100 Radiol, DK-2100 Copenhagen, Denmark
Titolo Testata:
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
fascicolo: 5, volume: 70, anno: 2001,
pagine: 657 - 661
SICI:
0022-3050(200105)70:5<657:BRQIHD>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; GLUCOSE CONSUMPTION; OXIDATIVE STRESS; BLOOD-FLOW; METABOLISM; ATROPHY; RISK; PET;
Keywords:
Huntington's disease; benzodiazepine receptor; SPECT-iomazenil;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Pinborg, LH Rigshosp, Neurobiol Res Unit 9201, Blegdamsvej, DK-2100 Copenhagen, Denmark Rigshosp Blegdamsvej Copenhagen Denmark DK-2100 agen, Denmark
Citazione:
L.H. Pinborg et al., "Benzodiazepine receptor quantification in Huntington's disease with [I-123]iomazenil and SPECT", J NE NE PSY, 70(5), 2001, pp. 657-661

Abstract

Objectives-Increasing evidence suggests that metabolic changes predate neuronal death in Huntington's disease and emission tomography methods (PET and SPECT) have shown changes in glucose consumption and receptor function inearly and possibly even presymptomatic disease. Because the GABA(A)-benzodiazepine receptor complex (BZR) is expressed on virtually all cerebral neurons BZR density images may be used to detect neuronal death. In this study the regional cerebral [I-123]iomazenil binding to BZR was determined in patients with Huntington's disease and normal controls by a steady state method and SPECTMethods-Seven patients mildly to moderately affected by Huntington's disease and seven age matched controls were studied. Brain CT was performed on all subjects. In each subject two [I-123]iomazenil-SPECT measurements were acquired-one with and one without infusion of flumazenil. The affinity constant of flumazenil (Kd) was calculated from the paired distribution volumes (DV) and the free plasma flumazenil concentration. The distribution volume of [I-123]iomazenil in the unblocked condition (DV0) reflects the ratio between BZR density and Kd. Results-Flumazenil kd was similar in the Huntington's disease group and the control group (11.3 v 11.2 mM). For the Huntington's disease group a 31% reduction in striatal DV0 (p=0.03) was found. In the cortical regions, DV0 was similar in patients and in controls. In Huntington's disease, DV0 correlated significantly with functional capacity (p=0.04) and chorea symptoms (p=0.02). The clinically least affected patients displayed DV(0)s within therange of those of the control group (19-35 ml/ml). Conclusions-The finding of an unchanged Iid of flumazenil in patients indicates that the BZR is functionally intact in Huntington's disease. That is,the reduction in DV0 for BZR represents a selective decrease in the numberof striatal BZRs. DV0 significantly correlated with functional loss and [I-123]iomazenil-SPECT could be an important tool for validation of the effect of future therapeutic strategies aimed at limiting oxidative stress and free radicals in Huntington's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 13:51:25